desipramine has been researched along with Breast Neoplasms in 3 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study compared the efficacy and safety of paroxetine and desipramine with those of placebo in the treatment of depressive disorders in adult women with breast cancer, stages I-IV." | 9.12 | A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. ( Evans, DL; Goodkin, R; Guo, Y; Lawson, D; Lawson, K; Lewison, B; Manatunga, AK; Musselman, DL; Nemeroff, CB; Penna, S; Porter, M; Somerset, WI, 2006) |
| "This study compared the efficacy and safety of paroxetine and desipramine with those of placebo in the treatment of depressive disorders in adult women with breast cancer, stages I-IV." | 5.12 | A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. ( Evans, DL; Goodkin, R; Guo, Y; Lawson, D; Lawson, K; Lewison, B; Manatunga, AK; Musselman, DL; Nemeroff, CB; Penna, S; Porter, M; Somerset, WI, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Germain, AR | 1 |
| Carmody, LC | 1 |
| Nag, PP | 1 |
| Morgan, B | 1 |
| Verplank, L | 1 |
| Fernandez, C | 1 |
| Donckele, E | 1 |
| Feng, Y | 1 |
| Perez, JR | 1 |
| Dandapani, S | 1 |
| Palmer, M | 1 |
| Lander, ES | 1 |
| Gupta, PB | 1 |
| Schreiber, SL | 1 |
| Munoz, B | 1 |
| Szpunar, MJ | 1 |
| Burke, KA | 1 |
| Dawes, RP | 1 |
| Brown, EB | 1 |
| Madden, KS | 1 |
| Musselman, DL | 1 |
| Somerset, WI | 1 |
| Guo, Y | 1 |
| Manatunga, AK | 1 |
| Porter, M | 1 |
| Penna, S | 1 |
| Lewison, B | 1 |
| Goodkin, R | 1 |
| Lawson, K | 1 |
| Lawson, D | 1 |
| Evans, DL | 1 |
| Nemeroff, CB | 1 |
1 trial available for desipramine and Breast Neoplasms
| Article | Year |
|---|---|
A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Breast; Breast Neoplasms; Comorbid | 2006 |
2 other studies available for desipramine and Breast Neoplasms
| Article | Year |
|---|---|
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
Topics: Amides; Breast Neoplasms; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Humans; Neopla | 2013 |
The antidepressant desipramine and α2-adrenergic receptor activation promote breast tumor progression in association with altered collagen structure.
Topics: Adenocarcinoma; Adrenergic alpha-2 Receptor Agonists; Animals; Antidepressive Agents, Tricyclic; Apo | 2013 |